Evidence map›Paper›PMID 28404012›Full record

ArticleThe lancet. Gastroenterology & hepatology2017

A non-endoscopic device to sample the oesophageal microbiota: a case-control study.

Daffolyn R Fels Elliott, Alan W Walker, Maria O'Donovan, Julian Parkhill, Rebecca C Fitzgerald

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The lancet. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 104 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.

  1. Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022
    Pooled it
  2. Article
  3. Screening for Barrett's esophagus and esophageal adenocarcinoma: recent advances and next steps.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Virulence · 2025
    Review
  12. Review
  13. Article
  14. New Approaches to Screening for Barrett Esophagus.Gastroenterology & hepatology · 2025
    Article
  15. Review
  16. Intratumoral microbiota: a new force in the development and treatment of esophageal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  17. Review
  18. Article
  19. Review
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Daffolyn R Fels ElliottMedical Research Centre Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.
Alan W WalkerPathogen Genomics Group, Wellcome Trust Sanger Institute, Hinxton, UK; Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, UK.
Maria O'DonovanDepartment of Histopathology, Cambridge University Hospital NHS Trust, Cambridge, UK.
Julian ParkhillPathogen Genomics Group, Wellcome Trust Sanger Institute, Hinxton, UK.
Rebecca C FitzgeraldMedical Research Centre Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK. Electronic address: RCF29@MRC-CU.cam.ac.uk.
Hutchison/MRC Research Centre · GBWellcome Sanger Institute · GBCambridge University Hospitals NHS Foundation Trust · GB

Funding

Cancer Research UK 15874Medical Research CouncilWellcome Trust
6 · The paper itself

Abstract

backgroundThe strongest risk factor for oesophageal adenocarcinoma is reflux disease, and the rising incidence of this coincides with the eradication of Helicobacter pylori, both of which might alter the oesophageal microbiota. We aimed to profile the microbiota at different stages of Barrett's carcinogenesis and investigate the Cytosponge as a minimally invasive tool for sampling the oesophageal microbiota.

methodsIn this case-control study, 16S rRNA gene amplicon sequencing was done on 210 oesophageal samples from 86 patients representing the Barrett's oesophagus progression sequence (normal squamous controls [n=20], non-dysplastic [n=24] and dysplastic Barrett's oesophagus [n=23], and oesophageal adenocarcinoma [n=19]), relevant negative controls, and replicates on the Illumina MiSeq platform. Samples were taken from patients enrolled in the BEST2 study at five UK hospitals and the OCCAMS study at six UK hospitals. We compared fresh frozen tissue, fresh frozen endoscopic brushings, and the Cytosponge device for microbial DNA yield (qPCR), diversity, and community composition.

findingsThere was decreased microbial diversity in oesophageal adenocarcinoma tissue compared with tissue from healthy control patients as measured by the observed operational taxonomic unit (OTU) richness (p=0·0012), Chao estimated total richness (p=0·0004), and Shannon diversity index (p=0·0075). Lactobacillus fermentum was enriched in oesophageal adenocarcinoma (p=0·028), and lactic acid bacteria dominated the microenvironment in seven (47%) of 15 cases of oesophageal adenocarcinoma. Comparison of oesophageal sampling methods showed that the Cytosponge yielded more than ten-times higher quantities of microbial DNA than did endoscopic brushes or biopsies using quantitative PCR (p<0·0001). The Cytosponge samples contained the majority of taxa detected in biopsy and brush samples, but were enriched for genera from the oral cavity and stomach, including Fusobacterium, Megasphaera, Campylobacter, Capnocytophaga, and Dialister. The Cytosponge detected decreased microbial diversity in patients with high-grade dysplasia in comparison to control patients, as measured by the observed OTU richness (p=0·0147), Chao estimated total richness (p=0·023), and Shannon diversity index (p=0·0085).

interpretationAlterations in microbial communities occur in the lower oesophagus in Barrett's carcinogenesis, which can be detected at the pre-invasive stage of high-grade dysplasia with the novel Cytosponge device. Our findings are potentially applicable to early disease detection, and future test development should focus on longitudinal sampling of the microbiota to monitor for changes in microbial diversity in a larger cohort of patients.

fundingCancer Research UK, National Institute for Health Research, Medical Research Council, Wellcome Trust, The Scottish Government (RESAS).

Indexed as

MicrobiotaAdenocarcinomaAdultAgedAged, 80 and overBarrett EsophagusBiopsyCase-Control StudiesCytodiagnosisDisease ProgressionEsophageal NeoplasmsEsophagoscopyEsophagusFemaleHumansMale

Identifiers

PMID28404012
PMCPMC5656094
OpenAlexW2540631373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.